The drug ACTEMRA contains one active pharmaceutical ingredient (API):
Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia.
Below package inserts are available for further reading:
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Australia Brazil Canada Ecuador Hong Kong New Zealand Singapore Tunisia United States South Africa
This drug has been assigned below unique identifiers within the countries it is being marketed: